Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Upstart Holdings Inc (UPST) Price & Performance

Novartis AGTrade
Upstart Holdings IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Upstart Holdings Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Upstart Holdings Inc trades at $29.9 (market cap $2.94B). The key difference: Novartis AG is far larger — about 101.4× Upstart Holdings Inc's market cap, and Novartis AG pays a 3.02% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.

NVSUPST
Market Cap
$298.18B$2.94B
Sector
HealthFinancials
52-Week High
$168.62$73.76
52-Week Low
$119.31$24.22
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

Upstart Holdings Inc

Upstart (UPST) trades at $31.09, up 4.64% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth of 42% year-over-year and a return to GAAP profitability, with loan originations surging 50%. However, it has missed EPS expectations for three consecutive quarters. The stock is supported by a consensus analyst price target of $47.20, implying significant upside, but faces headwinds from high interest rates and competitive pressures.

The outlook is mixed: strong loan growth and AI-driven underwriting improvements offer growth potential, but recent earnings misses, a high P/E ratio of 59.79, and negative operating cash flow in 2025 pose risks. Investor sentiment is cautiously optimistic, with 45% of analysts rating it a Buy, though volatility from macroeconomic factors remains a key concern for shareholders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Upstart Holdings Inc

Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.

Read more on UPST